Paris Cedex 13

• Avalglucosidase alfa French post-trial access for participants with Pompe disease Ended recruitment
  2024-514773-22-00 6 2022-07-11 Glycogen storage disease type II
• Study of setmelanotide in patients with obesity with specific genetic variants Ended recruitment
  2023-507634-24-00 5 2022-05-20 Improper function of certain messenger materials in the body that cont
• A Phase 3 Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant Ended recruitment
  2023-508897-27-00 5 2022-04-28 Multiple Myeloma
• Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanc … Ended recruitment
  2023-510097-14-00 5 2022-04-15 Patients with MMR deficient relapse or advanced / metastatic endometri
• Phase 3 Study of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis Ended recruitment
  2023-506359-68-00 5 2022-04-08 Active Proliferative Lupus Nephritis
• Assessment of Flecainide to Lower the patent foramen Ovale closure risk of Atrial arrhythmia or Tachycardia Ended recruitment
  2024-513324-42-00 5 2022-03-23 Patent Foramen Ovale Closure Atrial Arrhytmia or Tachycardia
• Long-term follow-up study to evaluate durability of treatment response in previous bepirovirsen study participants (B-Sure). Ended recruitment
  2023-506867-33-01 4 2022-01-25 Chronic Hepatitis B
• FILOCLL14 - STAIR : "Open-label, phase 2 study investigating the STop and restart Acalabrutinib In fRrail patients with previously untreated … Ended recruitment
  2024-513936-80-00 4 2021-11-12 elderly patients (> 70 years) with CLL or SLL
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with Systemic Lupus Erythematosus (ALLEGORY) Ended recruitment
  2023-504774-38-00 5 2021-11-04 Systemic Lupus Erythematosus (SLE)
• A Phase 3 Trial of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treat … Ended recruitment
  2023-507698-16-00 5 2021-10-14 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322
• CORTICOP_Comparison of corticosteroids versus placebo on duration of ventilatory support during severe acute exacerbations of COPD patients … Ended recruitment
  2024-516651-41-00 5 2021-10-08 COPD : chronic obstructive Pulmonary disease
• Evaluation of two maintenance therapies (OSE2101 alone or in combination with pembrolizumab) versus best supportive care in patient with pla … Ended recruitment
  2024-516096-32-00 4 2021-08-05 Platinum sensitive recurrent ovarian cancer
• A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation (ATLAS) Ended recruitment
  2023-505641-12-00 5 2021-07-27 Amyotrophic Lateral Sclerosis (ALS) associated with SOD1 gene mutation
• Hydrocorticose and vasopressin in post-resuscitation syndrome Ended recruitment
  2024-516373-77-00 5 2021-07-18 Adult cardiac arrest patients with sustained ROSC and hemodynamic fail
• A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr … Ended recruitment
  2023-504684-16-00 5 2021-06-05 follicular lymphoma (FL) and marginal zone lymphoma (MZL)
• Double blind, multicentric, randomized, placebo-controlled trial, evaluating the efficacy of 24-month of bezafibrate in primary sclerosing c … Ended recruitment
  2024-511658-28-01 5 2021-04-06 primary sclerosing cholangitis
• A clinical study to assess the effectiveness and safety of LOXO-305 compared to standard of care treatment chosen by the Investigator in pat … Ended recruitment
  2023-507695-52-00 5 2021-03-05 Mantle cell lymphoma
• FIBRAPLO - Haplo-identical transplantation in patients with myleofibrosis Ended recruitment
  2024-513325-23-00 4 2021-02-03 Myelofibrosis
• KILT - A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERA … Ended recruitment
  2024-513252-15-00 4 2021-01-28 IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA
• A study of safety and efficacy of NBI-74788 in Classic Congenital Adrenal Hyperplasia Ended recruitment
  2023-509171-16-00 5 2020-11-23 Classic Congenital Adrenal Hyperplasia (CAH)
• Safety and Efficacy Study of Epcoritamab in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome Ended recruitment
  2023-504828-25-00 9 2020-11-16 Chronic Lymphocytic Leukemia
• Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma Ended recruitment
  2023-507419-37-00 5 2020-06-25 Plasma cell myeloma
• Phase III study of GSK2857916, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in participants with relapsed … Ended recruitment
  2023-510537-28-00 5 2020-05-15 Multiple Myeloma
• A study for subjects after organ or cell transplantation after failure of prior treatment Ended recruitment
  2024-516622-57-00 5 2020-05-06 Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Dise

Showing 217–240 of 312 trials